Trending NewsTrending NewsNASDAQ:MRNA Moderna (MRNA) Stock Price, News & Analysis $158.07 +12.45 (+8.55%) Closing price 09/17/2026 04:00 PM EasternExtended Trading$161.12 +3.06 (+1.93%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Moderna Stock (NASDAQ:MRNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Moderna alerts:Sign Up Key Stats Today's Range$149.50▼$161.9650-Day Range$53.86▼$174.3852-Week Range$22.28▼$176.66Volume19.14 million shsAverage Volume25.01 million shsMarket Capitalization$63.11 billionP/E RatioN/ADividend YieldN/APrice Target$76.72Consensus RatingHold Company Overview Moderna, Inc. is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions. The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements. Stéphane Bancel has served as the company’s chief executive officer, while Noubar Afeyan is its founder and executive chairman.AI Generated. May Contain Errors. Read More Moderna Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreMRNA MarketRank™: Moderna scored higher than 43% of companies evaluated by MarketBeat, and ranked 647th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingModerna has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 7 buy ratings, 12 hold ratings, and 5 sell ratings.Downside RiskModerna has a consensus price target of $76.72, representing about 51.5% downside from its current price of $158.07.Amount of Analyst CoverageModerna has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Moderna's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moderna are expected to grow in the coming year, from ($6.09) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moderna is -19.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moderna is -19.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioModerna has a P/B Ratio of 7.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Moderna's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.99% of the float of Moderna has been sold short.Short Interest Ratio / Days to CoverModerna has a short interest ratio ("days to cover") of 0.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moderna has recently decreased by 25.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldModerna does not currently pay a dividend.Dividend GrowthModerna does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.40 News SentimentModerna has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 35 news articles for Moderna this week, compared to 9 articles on an average week.Search Interest102 people have searched for MRNA on MarketBeat in the last 30 days. This is an increase of 364% compared to the previous 30 days.MarketBeat Follows58 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 1,350% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,862,280.00 in company stock.Percentage Held by Insiders10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Moderna's insider trading history. Receive MRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRNA Stock News HeadlinesBiotech Stocks To Research - September 15th2 hours ago | americanbankingnews.comModerna continues volatile trading with 9% gainSeptember 17 at 6:34 PM | seekingalpha.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 18 at 1:00 AM | American Alternative (Ad)Why Are Moderna (MRNA) Shares Soaring TodaySeptember 17 at 6:34 PM | finance.yahoo.comInsider Selling: Moderna (NASDAQ:MRNA) President Sells 40,294 Shares of StockSeptember 17 at 6:22 AM | insidertrades.comModerna (NASDAQ:MRNA) CFO James Mock Sells 34,836 SharesSeptember 15 at 4:07 AM | insidertrades.comModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow ItModerna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.September 6, 2026 | marketbeat.comInsider Selling: Moderna (NASDAQ:MRNA) Insider Sells 3,471 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines MRNA Stock Analysis - Frequently Asked Questions How have MRNA shares performed this year? Moderna's stock was trading at $29.49 at the start of the year. Since then, MRNA stock has increased by 436.0% and is now trading at $158.07. How were Moderna's earnings last quarter? Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings data on Friday, July, 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. The business's revenue was up 2.1% on a year-over-year basis. Read the conference call transcript. When did Moderna IPO? Moderna (MRNA) raised $604 million in an IPO on Friday, December 7th 2018. The company issued 26,275,993 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. Who are Moderna's major shareholders? Moderna's top institutional investors include BlackRock Inc. (7.66%), Theleme Partners LLP (2.02%), Wellington Management Group LLP (0.62%) and Merck & Co. Inc. (0.58%). Insiders that own company stock include Stephen Hoge, Shannon Thyme Klinger, James M Mock, Abbas Hussain, Noubar Afeyan and Arpa Garay. View institutional ownership trends. How do I buy shares of Moderna? Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moderna own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings7/31/2026Today9/17/2026Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum9/23/2026Next Earnings (Estimated)11/05/2026Investor Day 202611/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MRNA's financial health is in the Green zone, according to TradeSmith. MRNA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MRNA CIK1682852 Webwww.modernatx.com Phone(617) 714-6500FaxN/AEmployees4,700Year Founded2010Price Target and Rating Average Price Target for Moderna$76.72 High Price Target$180.00 Low Price Target$18.00 Potential Upside/Downside-51.5%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)($7.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.82 billion Net Margins-141.43% Pretax Margin-138.55% Return on Equity-28.30% Return on Assets-19.39% Debt Debt-to-Equity Ratio0.09 Current Ratio2.29 Quick Ratio2.18 Sales & Book Value Annual Sales$2.21 billion Price / Sales28.56 Cash FlowN/A Price / Cash FlowN/A Book Value$22.14 per share Price / Book7.14Miscellaneous Outstanding Shares399,236,000Free Float356,119,000Market Cap$63.11 billion OptionableOptionable Beta1.10 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:MRNA) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump's new AI tirade hurting GOP?President Trump says AI will become the greatest economic development engine in history, dismissing fears of d...Stansberry Research | SponsoredThis #1 stock for the next AI boom?A new category of AI-powered device is reportedly in development, one that could trigger what some AI scientis...InvestorPlace | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
